898 related articles for article (PubMed ID: 11058576)
1. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
2. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
3. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
4. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes.
Siebenkotten IM; Carstens C; Koch N
J Immunol; 1998 Apr; 160(7):3355-62. PubMed ID: 9531295
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.
Sievers E; Neumann J; Raftery M; SchOnrich G; Eis-Hübinger AM; Koch N
Immunology; 2002 Sep; 107(1):129-35. PubMed ID: 12225371
[TBL] [Abstract][Full Text] [Related]
6. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
7. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
8. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
9. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.
Pinet V; Malnati MS; Long EO
J Immunol; 1994 May; 152(10):4852-60. PubMed ID: 8176208
[TBL] [Abstract][Full Text] [Related]
10. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
12. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
13. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
[TBL] [Abstract][Full Text] [Related]
15. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
16. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites.
Rajnavölgyi E; Horváth A; Gogolák P; Tóth GK; Fazekas G; Fridkin M; Pecht I
Eur J Immunol; 1997 Dec; 27(12):3105-14. PubMed ID: 9464794
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
Adams S; Humphreys RE
Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
[TBL] [Abstract][Full Text] [Related]
18. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
[TBL] [Abstract][Full Text] [Related]
19. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
20. Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells.
Ceppellini R; Frumento G; Ferrara GB; Tosi R; Chersi A; Pernis B
Nature; 1989 Jun; 339(6223):392-4. PubMed ID: 2786148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
